ea0098c42 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023
Romina Luca Maria
, Cecilia Vazquez Eliana
, Waisberg Federico
, Catani Greta
, Oviedo Ana
, Musumeci Martina
, Rodriguez Andres
, Bortz Marcos
, Esteso Federico
, Chacon Matias
, Manuel Oconnor Juan
, Racioppi Silvina
Background: Lutetitum-177 (Lu-DOTATE) is an approved treatment regimen for patients with advanced neuroendocrine tumors (NETs). Improving patient experience is one of main goals of a cancer treatment plan. "Time-toxicity" describes the period that patients spend in doing administrative or medical procedures, including medical visits, scans, lab analyses, emergency room admissions, drug applications and hospitalizations. Modern therapies are usually approved after an im...